HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder.

AbstractCONTEXT:
Uroplakin II is a 15-kDa protein component of the urothelial plaques that enhance the permeability barrier and strength of the urothelium. Studies have shown uroplakin II messenger RNA to be expressed in bladder cancer tissues and peripheral blood of patients with urothelial carcinoma. Little is known about the protein expression of uroplakin II in urothelial carcinoma, possibly because of the absence of a commercially available uroplakin II antibody. Pathologists have used the uroplakin III antibody (AU1) to identify tumors of urothelial origin; however, the use of AU1 is limited because of its poor sensitivity.
OBJECTIVES:
To evaluate a newly developed mouse monoclonal uroplakin II antibody (BC21) in urothelial carcinoma and to compare it with previously developed mouse monoclonal uroplakin III (BC17 and AU1).
DESIGN:
Uroplakin II and III antibodies were optimized for staining using a horseradish peroxidase-polymer detection system and were visualized with 3,3'-diaminobenzidine.
RESULTS:
BC21, BC17, and AU1 demonstrated sensitivities in urothelial carcinoma of the bladder of 79% (44 of 56), 55% (31 of 56) (P = .002), and 34% (19 of 56) (P < .001), respectively. Subsequently, the increased staining sensitivity and intensity of BC21, compared with BC17, was validated in a larger study (134 of 174; 77% and 94 of 174; 54%, respectively) (P < .001). BC21 was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostatic and renal carcinomas.
CONCLUSIONS:
The mouse monoclonal uroplakin II antibody (BC21) demonstrated superior sensitivity and specificity in urothelial carcinoma, compared with uroplakin III (BC17 and AU1), suggesting its advantages in the differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin.
AuthorsLaura L Hoang, David E Tacha, Weimin Qi, Charlie Yu, Ryan E Bremer, Joseph Chu, Thomas S Haas, Liang Cheng
JournalArchives of pathology & laboratory medicine (Arch Pathol Lab Med) Vol. 138 Issue 7 Pg. 943-9 (Jul 2014) ISSN: 1543-2165 [Electronic] United States
PMID24978921 (Publication Type: Comparative Study, Evaluation Study, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Biomarkers, Tumor
  • UPK2 protein, human
  • UPK3A protein, human
  • Uroplakin II
  • Uroplakin III
Topics
  • Animals
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody Specificity
  • Biomarkers, Tumor (immunology, metabolism)
  • Blotting, Western
  • Carcinoma, Transitional Cell (diagnosis, metabolism)
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Mice
  • Pregnancy
  • Tissue Distribution
  • Urinary Bladder Neoplasms (diagnosis, metabolism)
  • Uroplakin II (immunology, metabolism)
  • Uroplakin III (immunology, metabolism)
  • Urothelium (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: